Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Cancer prevention
Study Phase
Phase 3
Study Completion Date
2018-11-10
NCT01169259Uploaded 03-19-2021
Available for Download
PDS UID: Multiple_Brigham_454
Vitamin D and Omega-3 Trial (VITAL)
Provider Information
Provider Data DescriptionThe VITamin D and OmegA-3 TriaL (VITAL) was a randomized factorial clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) ended on December 31, 2017. The primary aims were: 1. To test whether vitamin D3 supplementation reduces the risk of (a) total cancer (excluding non-melanoma skin cancer) and (b) major CVD events (a composite endpoint of myocardial infarction [MI], stroke, and cardiovascular mortality). 2. To test whether EPA+DHA supplementation reduces the risk of (a) total cancer (excluding non-melanoma skin cancer) and (b) major CVD events. Secondary aims were: 1. To test whether vitamin D3 or EPA+DHA supplementation reduces the risk of (a) incident colorectal cancer, (b) incident breast cancer (in women), (c) incident prostate cancer (in men), and (d) total cancer mortality. 2. To test whether vitamin D3 or EPA+DHA supplementation reduces the risk of (a) an expanded composite cardiovascular endpoint of MI, stroke, cardiovascular mortality, and coronary revascularization (i.e., coronary artery bypass grafting [CABG] or percutaneous coronary intervention [PCI]) and (b) the individual components of the primary cardiovascular endpoint, particularly total CVD mortality.
SponsorBrigham and Women's Hospital
Data ProviderBrigham and Women's Hospital
Partial set or SubsetComposite
Patients in dataset25871
# of Patients Control25871
# of Patients Experimental0
DOIhttps://doi.org/10.34949/n4c7-zm25
CDISC StandardNot CDISC
Study ArmsBoth comparator and experimental arm data
Clinical Trials.gov Information
Brief SummaryThe VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention observational follow-up of study participants is ongoing.
ConditionsCancer
Cardiovascular Disease
Intervention TypeDietary Supplement: vitamin D3
Drug: omega-3 fatty acids (fish oil)
Dietary Supplement: Vitamin D3 placebo
Dietary Supplement: Fish oil placebo
Drug(s)Drug: omega-3 fatty acids (fish oil)
Total Enrolled25871
RandomizationRandomized
Blinding MethodTriple
Arms InterventionVitamin D + fish oil - Active Comparator
Vitamin D + fish oil placebo - Active Comparator
Vitamin D placebo + fish oil - Active Comparator
Vitamin D placebo + fish oil placebo - Placebo Comparator
Secondary IDU01CA138962
PubMed (PMID)26767629
25864623
21986389
30415629
30415637
31750855
32062040
36378553
36285795
36098968
35361440
35082139
34932079
34853363
34678177
34543425
34366734
33724323
33513226
33206192
32749491
32205068
31923341
31895658
31733345
31699704
31669447
29526608
Collaborator(s)National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Office of Dietary Supplements (ODS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Center for Complementary and Integrative Health (NCCIH)
Pharmavite LLC
Pronova BioPharma
BASF
Region(s)United States
Age Range50 Years and older (ADULT, OLDER_ADULT)
Files:
PROTOCOLManson_VITAL_protocol_NEJM_2019.pdf
CRFNot Provided
Data DictionaryVITAL_data_dictionary_2023_1.docx
DATA SUMMARYPDS_DATA_PROFILE_CREATED_VITAL_trial_NEJM_2022.xlsx
DATA SUMMARYMacFarlane VITAL VitD fish oil knee pain ArthRheum 2020.pdf
CURATED OR COMPOSITE DATA (COMPARATOR ARM)VITAL_trial_NEJM_2022.sas7bdat
CURATED OR COMPOSITE DATA (COMPARATOR ARM)vitalstatin.sas7bdat
CURATED OR COMPOSITE DATA (COMPARATOR ARM)vitalkneepain111623.sas7bdat
© 2024 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use